Scleroderma heart disease.

B. Marasini, M. Massarotti, R. Cossutta

Research output: Contribution to journalArticle

Abstract

Heart disease is a frequent and often severe feature of systemic sclerosis (scleroderma). Cardiomyopathy, with ventricular diastolic dysfunction and arrhythmias, is the most important form, since it is associated with a very poor prognosis. The current challenge is to define its pattern and identify individuals at risk, but evaluation in vivo may be hard to perform. The aim of this review is to provide an update on the clinical aspects of scleroderma heart disease and the early pivotal role that coronary microcirculation dysfunction plays in its development. A discussion of the diagnostic tools now available for this frequently asymptomatic condition will be provided. Treatment options will be reviewed, even though no cure for systemic sclerosis exists, and the current therapy of diastolic dysfunction remains unsatisfactory.

Original languageEnglish
Pages (from-to)609-614
Number of pages6
JournalInternational Journal of Immunopathology and Pharmacology
Volume18
Issue number4
Publication statusPublished - Oct 2005

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology

Cite this

Marasini, B., Massarotti, M., & Cossutta, R. (2005). Scleroderma heart disease. International Journal of Immunopathology and Pharmacology, 18(4), 609-614.